<DOC>
	<DOCNO>NCT00886028</DOCNO>
	<brief_summary>Liposomal doxorubicin consist doxorubicin encapsulate liposome compose phosphatidylcholine cholesterol . Liposomal doxorubicin extravasate tumor abnormal vascular endothelium may penetrate normal tissue lower toxicity increase efficiency . Combining Liposomal doxorubicin cisplatin could effective new chemotherapy treatment malignant pleural mesothelioma . Hypothesis : Liposomal doxorubicin combine cisplatin could increase response rate chemotherapy , progression free survival overall survival patient malignant pleural mesothelioma .</brief_summary>
	<brief_title>Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin Patients With Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>Background : Malignant pleural mesothelioma ( MPM ) invasive primary neoplasm associate rapid progression . It usually diagnose fifth seventh decade life , strong male predominance . 80 % patient MPM history asbestos exposure . MPM develop 10 % people asbestos exposure , suggest factor may important development malignancy . MPM classify three pathological type : epithelial , sarcomatoid , mixed . The epithelial type represent 50 % case whether sarcomatoid type the15 % . Clinically sarcomatoid type relate poor prognosis compare epithelial mixed type MPM present unique challenge regard diagnosis , stag , treatment . Survival rate approximately 6 month patient without surgical treatment . 90 % patient MPM candidate surgical treatment arrive advanced stage poor lung function . In addition , surgery single modality fail improve survival , several research explore use combine modality therapy incorporate radiation chemotherapy . Given prognosis patient advance MPM poor regardless type anticancer treatment , palliation symptom primary goal . Chemotherapy remain main palliative therapeutic modality , although either surgical intervention local radiation therapy may useful local control pain symptom often associate pleural fluid accumulation . Most single chemotherapeutic agent test MPM obtain response rate &lt; 20 % . The impact chemotherapy survival patient MPM remain uncertain . Platinum analogues extensively study MPM single combine regimen . There study patient MPM treat cisplatin 60 mg/m2 doxorubicin 60 mg/m2 day 1 3 4 week interval demonstrate response rate 20 25 % overall survival 10 month . Liposomal doxorubicin ( LD ) consist doxorubicin encapsulate liposome compose phosphatidylcholine cholesterol . LD extravasate tumor abnormal vascular endothelium may penetrate normal tissue lower toxicity increase efficiency . Combining LD cisplatin could effective new chemotherapy treatment MPM . Objective : Increase chemotherapy response rate , progression free survival overall survival patient MPM treat LD plus cisplatin palliative treatment MPM . Methods : We conduct prospective analytical study September 2006 April 2009 . Thirty patient epithelial , sarcomatoid biphasic histological confirm diagnosis MPM Instituto Nacional de Cancerología Instituto Nacional de Enfermedades Respiratorias include receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 week 6 cycle . During first cycle chemotherapy , scintigraphic image study do LD label Tc-99m ( LD-Tc-99m ) . The imaging study ( SPECT/CT ) do 1h administration evaluate biodistribution accumulation LD-Tc-99m tumoral tissue . Patients evaluate surgeon 2 cycle chemotherapy , surgery possible , chemotherapy continue tumor progression . Clinical biochemical evaluation obtain chemotherapy administration . An axial computed tomography request chemotherapy every 2 month first 6 month every 4 month follow 2 year . Treatment response accord RECIST criterion toxicity evaluate National Cancer Institute Common Toxicity Criteria version 3.0 . The statistical analysis make use SPSS v.10 software . For descriptive purpose , continuous variable summarize arithmetic mean , median , standard deviation ; categorical variable 95 % confidence interval . Disease-free progression over-all survival evaluate Kapplan-Meier .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients epithelial , sarcomatoid biphasic histological confirm diagnosis MPM Instituto Nacional de Cancerología Instituto Nacional de Enfermedades Respiratorias ECOG functional status 0 2 No renal function alteration ( GFR &gt; 50 % ) No hepatic function alteration Leucocytes 2,000/mcl Hemoglobin 10mg/dL Platelets 100,000/mcl Patients receive previous chemotherapy MPM Patients accept treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Malignant pleural mesothelioma</keyword>
	<keyword>Liposomal doxorubicin</keyword>
	<keyword>Progression free survival</keyword>
	<keyword>Patients receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 week 6 cycle</keyword>
	<keyword>Patients epithelial , sarcomatoid biphasic histological confirm diagnosis MPM</keyword>
</DOC>